2237 GMT - Jefferies lowers its price target on radiopharmaceutical company Clarity by 15% after pushing out the likely date of a key U.S. milestone for its 64Cu-SAR-bisPSMA product. Clarity hopes the product will become a new diagnostic imaging agent in prostate cancer. Analyst David Stanton now expects Clarity to receive U.S. reimbursement approval for the diagnostic in 2H of FY 2027, a year later than he had originally forecast. Jefferies's new price target is A$7.00/share, down from A$8.20 before. Clarity ended Monday at A$3.15. (david.winning@wsj.com; @dwinningWSJ)
(END) Dow Jones Newswires
March 03, 2025 17:37 ET (22:37 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.